Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up to $34.89

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $34.89, but opened at $36.51. Collegium Pharmaceutical shares last traded at $37.39, with a volume of 68,130 shares.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Tuesday. HC Wainwright raised shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Tuesday. Finally, Piper Sandler cut shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target for the company. in a research note on Friday, May 10th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Collegium Pharmaceutical Stock Performance

The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The business’s 50 day moving average is $32.65 and its 200 day moving average is $34.63. The stock has a market capitalization of $1.25 billion, a PE ratio of 15.63 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The firm had revenue of $144.92 million for the quarter, compared to analysts’ expectations of $147.04 million. On average, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the transaction, the director now directly owns 44,775 shares in the company, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the transaction, the director now directly owns 44,775 shares in the company, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the transaction, the chief financial officer now owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders have sold 105,502 shares of company stock worth $3,540,796 in the last three months. Corporate insiders own 3.98% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in COLL. Principal Financial Group Inc. lifted its position in shares of Collegium Pharmaceutical by 8.2% in the 2nd quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock worth $54,124,000 after purchasing an additional 128,003 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Collegium Pharmaceutical by 10.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,745 shares of the specialty pharmaceutical company’s stock worth $314,000 after purchasing an additional 959 shares during the period. Louisiana State Employees Retirement System lifted its position in shares of Collegium Pharmaceutical by 1.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $531,000 after purchasing an additional 300 shares during the period. SummerHaven Investment Management LLC lifted its position in shares of Collegium Pharmaceutical by 1.3% in the 2nd quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock worth $1,120,000 after purchasing an additional 452 shares during the period. Finally, Values First Advisors Inc. lifted its position in shares of Collegium Pharmaceutical by 6.6% in the 2nd quarter. Values First Advisors Inc. now owns 16,993 shares of the specialty pharmaceutical company’s stock worth $547,000 after purchasing an additional 1,057 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.